Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002162566> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2002162566 endingPage "990" @default.
- W2002162566 startingPage "990" @default.
- W2002162566 abstract "To develop an optimal treatment strategy that reduces low-density lipoprotein (LDL) cholesterol levels and improves adherence to therapy by reviewing clinical trials that define the dose-response characteristics for 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), bile acid sequestrants, and niacin.Data were obtained from a MEDLINE search of the English-language literature published from 1975 through November 1995 and from an extensive bibliography review.Controlled, clinical trials were reviewed if they evaluated 1) the effectiveness and toxicity of one LDL cholesterol-lowering agent (statins, bile acid sequestrants, or niacin, at two or more doses) or 2) monotherapy with two LDL cholesterol-lowering agents at defined doses used alone and in combination. Studies that had fewer than 10 patients in a treatment group or that selected patients on the basis of previous response to therapy were not included.Trials were reviewed for overall methodology, inclusion and exclusion criteria, sources of bias, and outcomes.Dose-response relations for bile acid sequestrants and statins are nonlinear, and most of their LDL cholesterol-lowering effects can be obtained with lower doses. The few dose-response studies of niacin that have been done suggest that most of niacin's high-density lipoprotein cholesterol-increasing effect can also be achieved with relatively low doses, but higher doses are needed to substantially reduce LDL cholesterol levels. If bile acid sequestrants or niacin are added to statin therapy, the effect of combined therapy on LDL cholesterol levels is additive.The nonlinear dose-response relation of statins, bile acid sequestrants, and niacin and their additive LDL cholesterol-lowering effect when used together suggest a strategy for treating hypercholesterolemia that may optimize effectiveness while minimizing adverse effects and cost." @default.
- W2002162566 created "2016-06-24" @default.
- W2002162566 creator A5084899052 @default.
- W2002162566 creator A5086498627 @default.
- W2002162566 date "1996-12-15" @default.
- W2002162566 modified "2023-09-30" @default.
- W2002162566 title "Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment" @default.
- W2002162566 doi "https://doi.org/10.7326/0003-4819-125-12-199612150-00011" @default.
- W2002162566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8967711" @default.
- W2002162566 hasPublicationYear "1996" @default.
- W2002162566 type Work @default.
- W2002162566 sameAs 2002162566 @default.
- W2002162566 citedByCount "83" @default.
- W2002162566 countsByYear W20021625662012 @default.
- W2002162566 countsByYear W20021625662013 @default.
- W2002162566 countsByYear W20021625662014 @default.
- W2002162566 countsByYear W20021625662015 @default.
- W2002162566 countsByYear W20021625662016 @default.
- W2002162566 countsByYear W20021625662017 @default.
- W2002162566 countsByYear W20021625662018 @default.
- W2002162566 countsByYear W20021625662020 @default.
- W2002162566 countsByYear W20021625662021 @default.
- W2002162566 countsByYear W20021625662023 @default.
- W2002162566 crossrefType "journal-article" @default.
- W2002162566 hasAuthorship W2002162566A5084899052 @default.
- W2002162566 hasAuthorship W2002162566A5086498627 @default.
- W2002162566 hasConcept C126322002 @default.
- W2002162566 hasConcept C168563851 @default.
- W2002162566 hasConcept C2776839432 @default.
- W2002162566 hasConcept C2776999253 @default.
- W2002162566 hasConcept C2778163477 @default.
- W2002162566 hasConcept C2778697171 @default.
- W2002162566 hasConcept C2779399885 @default.
- W2002162566 hasConcept C2780072125 @default.
- W2002162566 hasConcept C2780092750 @default.
- W2002162566 hasConcept C535046627 @default.
- W2002162566 hasConcept C71924100 @default.
- W2002162566 hasConcept C98274493 @default.
- W2002162566 hasConceptScore W2002162566C126322002 @default.
- W2002162566 hasConceptScore W2002162566C168563851 @default.
- W2002162566 hasConceptScore W2002162566C2776839432 @default.
- W2002162566 hasConceptScore W2002162566C2776999253 @default.
- W2002162566 hasConceptScore W2002162566C2778163477 @default.
- W2002162566 hasConceptScore W2002162566C2778697171 @default.
- W2002162566 hasConceptScore W2002162566C2779399885 @default.
- W2002162566 hasConceptScore W2002162566C2780072125 @default.
- W2002162566 hasConceptScore W2002162566C2780092750 @default.
- W2002162566 hasConceptScore W2002162566C535046627 @default.
- W2002162566 hasConceptScore W2002162566C71924100 @default.
- W2002162566 hasConceptScore W2002162566C98274493 @default.
- W2002162566 hasIssue "12" @default.
- W2002162566 hasLocation W20021625661 @default.
- W2002162566 hasLocation W20021625662 @default.
- W2002162566 hasOpenAccess W2002162566 @default.
- W2002162566 hasPrimaryLocation W20021625661 @default.
- W2002162566 hasRelatedWork W1541662874 @default.
- W2002162566 hasRelatedWork W1980031477 @default.
- W2002162566 hasRelatedWork W1982306380 @default.
- W2002162566 hasRelatedWork W2002162566 @default.
- W2002162566 hasRelatedWork W2005963193 @default.
- W2002162566 hasRelatedWork W2027762847 @default.
- W2002162566 hasRelatedWork W2046106543 @default.
- W2002162566 hasRelatedWork W2168423314 @default.
- W2002162566 hasRelatedWork W2412226342 @default.
- W2002162566 hasRelatedWork W2082908243 @default.
- W2002162566 hasVolume "125" @default.
- W2002162566 isParatext "false" @default.
- W2002162566 isRetracted "false" @default.
- W2002162566 magId "2002162566" @default.
- W2002162566 workType "article" @default.